Compare Novavax Inc (NVAX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs 22nd Century Group Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Novavax Inc is far larger — about 2927.6× 22nd Century Group Inc's market cap, and Novavax Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and 22nd Century Group Inc for 32 Days on average.
| NVAX | XXII | |
|---|---|---|
Market Cap | $1.82B | $621.67K |
Volume | 6,198,505 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $12.56 | $483.00 |
52-Week Low | $6.22 | $0.80 |
Typical Hold Time | 59 Days | 32 Days |
Enterprise Value | $1.39B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
